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Introduction {#sec1}
============

Alzheimer\'s disease (AD) impairs neural networks involved in cognitive function by affecting synaptic connections and causing neuronal degeneration ([@bib33], [@bib47], [@bib63]). Amyloid-β protein (Aβ), a small protein produced physiologically by proteolytic cleavages of the amyloid precursor protein (APP) ([@bib18]), has been long considered to play a primary role in this process ([@bib19]). Aβ has the ability to form a range of structurally distinct assemblies, which exert different toxic functions via different targets ([@bib4], [@bib9], [@bib15], [@bib19], [@bib21], [@bib24], [@bib30], [@bib39], [@bib44], [@bib45], [@bib54], [@bib74]). However, in neurons, the subcellular site and the regulation mechanism of Aβ production still remain to be determined ([@bib18]), as do the mechanisms of Aβ assembly into neurotoxic structures and the manner in which these structures encounter their target neurons.

We previously identified a population of neurotoxic Aβ assemblies, amylospheroids (ASPD), stable assemblies containing approximately 30 monomers ([@bib21], [@bib39], [@bib44], [@bib47]). ASPD bind to the neuron-specific α3 subunit of the Na^+^, K^+^-ATPase pump (NAKα3), with a *K*~*d*~ in the low nanomolar range, and induce neurodegeneration by impairing the pump activity ([@bib45]). Importantly, ASPD concentration correlated with disease severity and progression in patients ([@bib45]). Interestingly, ASPD levels were high in the cerebral cortex, where NAKα3-expressing neurons were lost, whereas their levels were low in the cerebellum, where NAKα3-expressing neurons were preserved. These findings showed that NAKα3 was a neurotoxic target of ASPD and also suggested a difference in the ability to form ASPD between brain regions ([@bib45]).

*In vitro* studies have shown that the pathway of ASPD assembly from Aβ monomers is distinct from those of other Aβ oligomers ([@bib39]). A key question remaining was how ASPD formation occurred *in vivo*. We reasoned that because the primary component of patient-derived ASPD appears to be Aβ ([@bib45]), ASPD formation should be linked to Aβ production from APP. Full-length APP is synthesized in the endoplasmic reticulum (ER) and transported through the Golgi apparatus to the *trans*-Golgi network (TGN), where the highest concentration of APP is found in neurons in steady state ([@bib17], [@bib20], [@bib81]). From the TGN, a population of APP is further transported in the TGN-derived secretory vesicles to the plasma membrane (PM) where it is either cleaved by α-secretase to produce a soluble molecule, sAPPα, or re-internalized via an endosomal/lysosomal degradation pathway ([@bib18]). Aβ has been reported to be generated from mature APP through β- and γ-secretase cleavages in the above sorting pathways that interconnect the TGN, the cell surface, and the endosomes ([@bib18]). Therefore we hypothesized that ASPD might also be generated in these pathways.

Proteasomes may also be involved in APP/Aβ degradation ([@bib75]). Proteasomes are present mainly in the cytoplasm in mammalian cells, but immune electron microscopy has shown that they can also be associated with the cytoplasmic surface of the ER in mammalian cells ([@bib46], [@bib52]). Membrane proteins like APP are retro-translocated from the ER to the cytoplasm and degraded by the ER-associated proteasomes. This process is termed ER-associated degradation (ERAD) ([@bib73]). In general, upward of 30% of newly synthesized proteins are degraded by proteasomes ([@bib60]), including APP and Aβ ([@bib75]). Proteasome activities are lower in AD brains than in age-matched control brains ([@bib26], [@bib27]), and proteomic studies have suggested that proteasome impairment might be a risk factor for AD ([@bib38], [@bib70]). We report here studies to determine the role of proteasomes in ASPD formation. Our approach was to inhibit the proteasome-mediated degradation of APP and Aβ and determine its effect on ASPD formation in mature neurons. For this purpose, we established an *in vitro* cellular system to monitor ASPD formation in neurons expressing APP-bearing mutations linked to familial early-onset AD. As summarized in the Graphical Abstract, we found that proteasome inhibition dramatically increased intra-neuronal ASPD levels and changed ASPD distribution from the axon to dendrites. ASPD were then secreted and killed neighboring NAKα3 neurons. These findings deepen our understanding of the formation and delivery of toxic Aβ oligomers in AD brains, which in the future may open up the possibility of developing anti-assembly drugs for AD by modifying APP/Aβ degradation.

Results {#sec2}
=======

Introduction of Human APP770 Gene Bearing the Early-Onset Mutations into Mature Hippocampal Neurons by Using an AAV Vector {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------

To establish a mature neuron-based system, we introduced human APP770 gene with a familial AD mutation into rat hippocampal neuronal cultures at 10 days *in vitro* (DIV) using an adeno-associated virus 1-derived (AAV) vector ([@bib37]) ([Transparent Methods](#mmc1){ref-type="supplementary-material"}, [Figure 1](#fig1){ref-type="fig"}A). Two types of mutations were selected. One was the Swedish mutation (APPswe), which results in the substitution of Lys^670^ and Met^671^, two amino acids adjacent to the β-secretase cleavage site, into Asn^670^ and Leu^671^, respectively ([@bib41]). The other was the Osaka mutation (APPosk), which involves deletion of the entire codon 693 encoding glutamate (corresponding to glutamate at position 22 of Aβ; accordingly designated as E22Δ) ([@bib69]). Western blot and immunocytochemistry confirmed that mature human APP was expressed in neurons transduced with either APPswe or APPosk gene ([Figures 1](#fig1){ref-type="fig"}B and 1C). The level of expressed human APP was on average 2.7 times (as to APPswe) or 5.1 times (as to APPosk) as much as that of endogenous rodent APP, based on quantification in western blots ([Figure 1](#fig1){ref-type="fig"}B). As reported previously ([@bib49]), the AAV vector showed tropism for neurons over astrocytes. In our study, transduction efficiency of rat hippocampal neurons with the AAV vector was usually \>85%. Consistently, in the AAV-infected cultures, the human APP770-specific antibody detected human APP770 protein in almost all the neurons ([Figure 1](#fig1){ref-type="fig"}C and enlarged views in insets) and minimal expression in astrocytes ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Expression of Human APP in Mature Neurons(A) Experiments were performed as shown here except for the staining in the upper panels of [Figure 5](#fig5){ref-type="fig"}A (performed at 30 DIV).(B) Representative western blot of whole lysates (10 μg/lane) of primary rat hippocampal neuronal cultures with or without AAV-APP transduction, detected by anti-APP or anti-actin antibody (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Arrows show *O*-glycosylated or *N*-glycosylated human APP, above which rat APP was also detected.(C) Primary rat hippocampal neuronal cultures, with or without AAV-APP transduction, were stained with antibodies against MAP2, GFAP, and human APP at 22 DIV (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Representative images are shown. Scale bar, 50 μm. An enlarged view of the field is shown in the insets.

Proteasome Inhibition Affects Aβ Metabolism {#sec2.2}
-------------------------------------------

We first examined the effect of proteasome inhibition on Aβ production by treating the AAV-transduced mature neurons with a proteasome inhibitor, MG132 (IC~50~ of 100 nM; [@bib71]), at 75 nM for 24 h. Because the rate-limiting step in Aβ production is cleavage of APP by BACE-1 ([@bib64]), we monitored cleavage levels using an Aβ N-terminal-end-specific antibody that does not cross-react with full-length APP. As shown in [Figure 2](#fig2){ref-type="fig"}A, proteasome inhibition markedly increased Aβ N-terminal-end-specific (N-terAβ) staining in human APP-transduced mature neurons. Although the degree of increase varied widely from neuron to neuron, N-terAβ staining appeared to increase in almost all the neurons ([Figures 2](#fig2){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}), consistent with human APP expression in almost all the neurons ([Figure 1](#fig1){ref-type="fig"}C). Similarly, we found that human APP770-specific staining increased markedly in the neuronal cell body after 24-h MG132 treatment ([Figure 2](#fig2){ref-type="fig"}B). At this time, Aβ assemblies were trimeric, as assessed by SDS-PAGE (red arrow in [Figure 3](#fig3){ref-type="fig"} left panel). Western blot showed that Aβ and human APP levels increased approximately 3- and 10-fold, respectively ([Figure 3](#fig3){ref-type="fig"}). We confirmed that proteasome inhibition did not accelerate Aβ secretion as the level of secreted Aβ, either Aβ~1-40~ or Aβ~1-42~, was not changed or even slightly decreased (\*p = 0.04 by Scheffé post hoc test; n = 4) after 24-h MG132 treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}). Collectively, these data showed that proteasome inhibition led to an increase in the steady-state level of Aβ in our system, either directly by inhibiting ERAD-mediated Aβ degradation or indirectly by increasing the APP available for Aβ production.Figure 2Effect of Proteasome Inhibition on Aβ and APP(A and B) Primary rat hippocampal neuronal cultures, with or without AAV-APP transduction, were treated with or without 75 nM MG132 for 24 h. The cultures were triple stained with DAPI, anti-MAP2, and anti-Aβ N-terminal end-specific (N-terAβ) antibodies in (A) or stained with DAPI, anti-MAP2, and anti-human APP770-specific antibodies in (B) ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). Representative images are shown. For each condition, left columns show the triple staining, whereas right columns show the corresponding DAPI/N-terAβ staining in (A) or DAPI/human APP770 staining in (B). An enlarged view is shown in the insets. Scale bar, 50 μm.See [Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}.Figure 3Effect of Proteasome Inhibition on Aβ and APPRepresentative western blot of whole lysates (8 μg/lane) of primary rat hippocampal neuronal cultures with or without AAV-APP transduction, treated with or without 75 nM MG132 for 24 h, detected by anti-Aβ N-terminal, anti-APP, or anti-actin antibody (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Left panel, Aβ appeared at the position of the trimer in SDS-PAGE (red arrowhead). The right lane represents western blot of synthetic Αβ~1-42~ (4 pmol/lane). Black arrows show monomer, dimer, and trimer positions. The asterisk indicates non-specific bands detected by anti-Aβ N-terminal antibodies. Middle panel, arrows show *O*-glycosylated or *N*-glycosylated human APP, above which rat APP was also detected. Right panel, green asterisk shows non-specific bands detected by an anti-actin antibody. See [Figure S2](#mmc1){ref-type="supplementary-material"}.

Inhibition of Proteasome Activities Increases ASPD Accumulation in Mature Neurons Expressing Human APP Bearing the Early-Onset Swedish Mutation {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------------

We next examined the effect of proteasome inhibition on ASPD formation using the APPswe transgene, which increases Aβ production by facilitating APP processing mediated by β-secretase without any change in the Aβ sequence ([@bib6], [@bib12]). As shown in [Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A, after 24-h treatment with MG132, APPswe-transduced neurons showed a marked increase in ASPD staining. Consistent with AAV tropism for neurons ([Figure 1](#fig1){ref-type="fig"}C), ASPD staining was increased essentially in microtubule-associated protein 2 (MAP2)-positive neurons, but rarely in glial fibroblast acidic protein (GFAP)-positive astrocytes, after 24-h MG132 treatment ([Figure 4](#fig4){ref-type="fig"}A left). However, whereas N-terAβ antibody staining was observed in some degree in almost all the neurons, only a limited population of the APPswe-transduced neurons showed an increased ASPD staining (arrowheads in [Figure S1](#mmc1){ref-type="supplementary-material"}). The level of ASPD staining thus does not simply correlate with N-terAβ staining. In contrast with APPswe-transduced neurons, untransduced neurons (without human APP) that produce only endogenous rodent Aβ rarely accumulate ASPD. This is reasonable because, owing to the three amino acid substitutions, Arg5Gly, His13Arg, and Tyr10Phe, rodent Aβ is less prone to form toxic, smaller aggregates when compared with human Aβ, resulting in higher resistance to the development of AD-like neuropathology ([@bib55]).Figure 4Proteasome Inhibition Increases Intra-neuronal ASPD Accumulation(A) Primary rat hippocampal neuronal cultures, with or without AAV-APPswe transduction, were treated with 75 nM MG132 for 24 h. The cultures were triple stained with antibodies against N-terAβ, MAP2, and DAPI on the right side, or against MAP2, GFAP, and ASPD (rpASD1) on the left side. Representative images are shown. Scale bar, 50 μm. In this work, ASPD were detected by immunohistochemical staining with ASPD-specific rpASD1 antibody or mASD3 antibody ([@bib44]), both of which have been used to detect ASPD in immunopathological studies of human brains ([@bib44], [@bib45]).(B) Primary rat hippocampal neuronal cultures, with or without AAV-APPswe transduction, were treated with 75 nM MG132 for the indicated time. The cultures were double stained with anti-ASPD rpASD1 antibody and DAPI. An enlarged view of the field enclosed by a hatched line is shown immediately on the right. Representative images are shown. Scale bar, 50 μm. The number of ASPD and MAP2 double-positive cells was counted by using a GE Healthcare Life Sciences "IN Cell Analyzer" system and is shown as "ASPD + neuron" in the inset upper panel. Then the total amount of rpASD1-immunostained ASPD that was detected in MAP2-positive cells was determined by using an IN Cell Analyzer and was divided by the number of ASPD and MAP2 double-positive cells, which is shown as "ASPD level/neuron" in the inset lower panel (mean ± SD, n = 3; Scheffé post hoc test; \*\*\*p \< 0.0001, \*\*p = 0.0006, \*p = 0.0176).See [Figures 1](#fig1){ref-type="fig"}, [S1](#mmc1){ref-type="supplementary-material"}, [S3](#mmc1){ref-type="supplementary-material"}, and [5](#fig5){ref-type="fig"}.

To confirm that proteasomal dysfunction caused the ASPD formation, we examined the concentration-dependent effects of various pharmacologically unrelated inhibitors on ASPD formation. In addition to a reversible inhibitor, MG132 ([Figure S3](#mmc1){ref-type="supplementary-material"}A), we examined an irreversible inhibitor, epoxomicin, (IC~50~ of ∼4 nM; [@bib28]; [Figure S3](#mmc1){ref-type="supplementary-material"}B), and an irreversible inhibitor, lactacystin, (IC~50~ of 4.8 μM; [@bib14]; [Figure S3](#mmc1){ref-type="supplementary-material"}C). All these proteasome inhibitors increased the neuronal ASPD staining at 24 h in a dose-dependent fashion ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}). Based on these observations, further experiments were performed using MG132 at 75 nM.

We next examined spatiotemporal change in ASPD staining after 75 nM MG132 treatment. As shown in [Figure 4](#fig4){ref-type="fig"}B, left columns, baseline levels of ASPD staining were detected in untransduced control cultures, which did not change after 24-h MG132 treatment (see quantification in [Figure 4](#fig4){ref-type="fig"}B right). In contrast with control cultures, MG132 treatment increased the ASPD levels substantially and significantly with time in APPswe-transduced neurons (see quantification in [Figure 4](#fig4){ref-type="fig"}B right). Initially, very diffuse ASPD staining was consistently detected in the APPswe-transduced neurons before proteasome inhibition (see images of AAV-APPswe at 0 h in [Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). This diffuse ASPD staining in neuronal cell bodies was usually accompanied with axonal ASPD staining that was co-stained by an axonal marker, an antibody against neurofilament heavy chain (arrows at 0 h in [Figure 4](#fig4){ref-type="fig"}B right and orange arrows in upper panels of Figure 5A). MG132 treatment for 6 h markedly increased the ASPD staining in neuronal cell bodies (representative image of the 6-h MG132 treatment: [Figure 4](#fig4){ref-type="fig"}B middle and right). At this time point, in addition to the axonal ASPD staining, dendritic ASPD staining appeared (arrowheads at 6 h in [Figure 4](#fig4){ref-type="fig"}B right). MG132 treatment for 24 h dramatically increased both the number of neurons that contained ASPD and the ASPD level in each neuron (an image of the 24-h MG132 treatment is shown in [Figure 4](#fig4){ref-type="fig"}B, middle and right; quantification on the right). Interestingly, at this stage, the axonal ASPD staining disappeared (orange arrows in lower panels of [Figure 5](#fig5){ref-type="fig"}A). Conversely, the dendritic ASPD staining became stronger, and its distribution changed (double-lined white arrows in lower panels of [Figure 5](#fig5){ref-type="fig"}A). At 6-h MG132 treatment, the dendritic ASPD staining was distributed along the entire length of the dendrite, all the way to its tip (arrowhead at 6 h in [Figure 4](#fig4){ref-type="fig"}B right). However, at 24-h treatment, the dendritic ASPD staining reached the dendritic branch points, but the staining at the tip had weakened and become patchy (double-lined arrows at 24 h in [Figure 4](#fig4){ref-type="fig"}B rightmost panel and double-lined white arrows in lower panels of [Figure 5](#fig5){ref-type="fig"}A). High-power images showed that ASPD mostly appeared to stay inside of the dendrites (orange arrows in [Figure 5](#fig5){ref-type="fig"}B), but some dendritic ASPD signals on MAP2-labeled dendrites (39.6% ± 4.7%; n = 7 and total count = 1,614) appeared on the surface proximal to the Bassoon staining (double-lined white arrows in [Figure 5](#fig5){ref-type="fig"}B). The spatiotemporal change in ASPD staining is schematically illustrated in [Figure 5](#fig5){ref-type="fig"}C. Thus proteasome inhibition markedly increased the intra-neuronal ASPD level in steady state and led to changes in its intra-neuronal distribution.Figure 5Proteasome Inhibition Changes ASPD Distribution from Axon to Dendrites(A) Upper panels: primary rat hippocampal neuronal cultures with AAV-APPswe transduction were quadruple stained at 30 DIV with the anti-ASPD rpASD1 antibody, anti-NFH antibody, anti-MAP2 antibody, and DAPI (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Lower panels: primary rat hippocampal neuronal cultures with AAV-APPswe transduction were treated with 75 nM MG132 for 24 h and quadruple stained at 22 DIV as in the upper panels. A representative image, along with the corresponding single red, green, or magenta image, is shown with 50-μm scale bars. Orange arrows mark the axon, whereas white double-lined arrows mark dendrites. ASPD were co-localized with NFH (orange arrows) in the upper panels, but co-localized with MAP2 (white double-lined arrows) in the lower panels.(B) APPswe-transduced primary rat hippocampal neuronal cultures were treated with 75 nM MG132 for 24 h. The cultures were triple stained with antibodies against MAP2, Bassoon, and ASPD (rpASD1) on the left side. Representative images are shown. Scale bar, 1 μm.(C) Spatiotemporal changes in the ASPD distribution observed in [Figures 3](#fig3){ref-type="fig"}B and [4](#fig4){ref-type="fig"}A are schematically shown in red.See [Figures 4](#fig4){ref-type="fig"} and [S19](#mmc1){ref-type="supplementary-material"}.

ASPD Accumulate in the *Trans*-Golgi Network {#sec2.4}
--------------------------------------------

Next, we examined the subcellular location of ASPD in the APPswe-transduced neurons by double labeling neurons with an ASPD-specific rpASD1 antibody and organelle-specific antibodies. Representative images and their single-channel images are shown in [Figures 6](#fig6){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}, respectively. Before MG132 treatment, the number of ASPD signals was small, but they were present mainly where the *trans*-Golgi network-38 (TGN38) signal ([@bib22]) was found (see arrowheads in enlarged views of TGN38/rpASD1 staining of [Figure 6](#fig6){ref-type="fig"}, and their line scans in [Figure 7](#fig7){ref-type="fig"}). With longer MG132 treatment, more ASPD accumulated at the TGN (compare 0-, 6-, and 24-h MG132 treatment in enlarged views of [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}). In contrast, ASPD staining was not co-localized with the ER marker, protein disulfide isomerase (PDI) ([@bib79]), or a *cis*-Golgi marker, GM130 ([@bib42]), without proteasome inhibition and only rarely co-stained with them at 6-h MG132 treatment (see arrowhead in lower part of [Figure 6](#fig6){ref-type="fig"}; their line scans in [Figure 7](#fig7){ref-type="fig"}). After 24-h MG132 treatment, more ASPD signals were found together with PDI and GM130 signals, but the coexistence rate in TGN38/ASPD appeared to be higher than that in PDI/ASPD or GM130/ASPD (compare staining of TGN38/ASPD with that of PDI or GM130/ASPD in [Figures 6](#fig6){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}). ASPD staining in mature neurons was also rarely co-localized with early endosome antigen 1 (EEA1) ([@bib3]) or lysosomal-associated membrane protein-1 (LAMP1) ([@bib8]) at 6-h MG132 treatment ([Figures 6](#fig6){ref-type="fig"}, single channel images in S4, and line scans in [Figure 7](#fig7){ref-type="fig"}). This basically remained the case at 24-h MG132 treatment, at which time the vast majority of ASPD staining did not overlap with EEA1 or LAMP1 staining, although some overlap of the ASPD signal with them was seen (see arrowheads in lower part of [Figure 6](#fig6){ref-type="fig"}). ASPD staining was rarely observed in untransduced neurons with or without MG132 treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}).Figure 6ASPD Accumulate in the *Trans*-Golgi of Mature NeuronsPrimary rat hippocampal neuronal cultures, with or without AAV-APPswe transduction, were treated with 75 nM MG132 for the indicated time. The cultures were double-stained with anti-ASPD rpASD1 antibody and antibody against organelle marker protein (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). A highly sensitive, quantitative single-photon-counting system employing avalanche photodiodes on a Zeiss LSM710 microscope was used to perform detailed analyses along the z axis in high-power views of each neuronal cell body doubly-stained with ASPD-specific rpASD1 antibody and an antibody against an organelle marker. Representative images obtained with a 100X oil objective lens are shown. An enlarged view of the field enclosed by a hatched line is shown below. Solid and hatched scale bars, 10 and 1 μm, respectively. Single red and green images for each time point are shown in [Figure S4](#mmc1){ref-type="supplementary-material"}. See also representative images of control cultures without AAV transduction in [Figure S5](#mmc1){ref-type="supplementary-material"}. See [Figures 7](#fig7){ref-type="fig"}, [S4](#mmc1){ref-type="supplementary-material"}, and [S5](#mmc1){ref-type="supplementary-material"}.Figure 7Line scans of ASPD Accumulate in the *Trans*-Golgi of Mature NeuronsPrimary rat hippocampal neuronal cultures, with or without AAV-APPswe transduction, were treated with 75 nM MG132 for the indicated time. The cultures were double stained with anti-ASPD rpASD1 antibody and antibody against organelle marker protein as in [Figure 6](#fig6){ref-type="fig"} (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Representative line scans of enlarged views shown in [Figure 6](#fig6){ref-type="fig"} are included. See [Figure 6](#fig6){ref-type="fig"}

Although the TGN has been presumed to be a sorting site for newly synthesized membrane and secretory proteins, recent studies suggested that the recycling endosomes (REs), detected by an antibody either against the transferrin receptor (TfR) or Rab11 ([@bib31]), may serve as a sorting hub to direct proteins to the PM ([@bib35]). Interestingly, we found that ASPD were present in the REs of APPswe-transduced neurons at 24-h MG132 treatment ([Figures 8](#fig8){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}), which is not surprising, given the close and dynamic cross-talk between the TGN and the REs in neurons ([@bib58]). However, whereas ASPD always appears to co-localize with the TGN, ASPD co-localization with the REs was rarely detected up to 6-h MG132 treatment. The results strongly support the idea that the TGN is the major and initial site of ASPD localization in mature neurons.Figure 8ASPD Are Also Present in the Recycling Endosomes of Mature NeuronsPrimary rat hippocampal neuronal cultures, with or without AAV-APPswe transduction, were treated with 75 nM MG132 for the indicated time. The cultures were double-stained with anti-ASPD rpASD1 antibody and anti-transferrin receptor (TfR) antibody (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Representative images obtained with a highly sensitive, direct photon-counting system with a 100X oil objective lens are shown. An enlarged view of the field enclosed by a hatched line is shown below. Solid and hatched scale bars, 10 and 1 μm, respectively. Single red and green images for each time point are shown in [Figure S6](#mmc1){ref-type="supplementary-material"}. See [Figure S6](#mmc1){ref-type="supplementary-material"}.

To further elucidate ASPD localization in the TGN, we used brefeldin A (BFA), a lactone antibiotic and ATPase inhibitor for protein transport (IC~50~ of 0.06 μg/mL in HCT116 cells; [@bib83]), which rapidly collapses the Golgi apparatus into the ER by inhibiting protein transport from the ER to the Golgi apparatus ([@bib43], [@bib62]). In our system, BFA treatment at 0.6 μg/mL was enough to destroy the Golgi structure without affecting the cell viability in untransduced neurons (compare neurons with the preserved Golgi structure \[orange arrow\] and those with BFA-destroyed Golgi structure \[green arrow\] in [Figure S7](#mmc1){ref-type="supplementary-material"}). When MG132-treated APPswe-transduced mature neurons were treated with 0.6 μg/mL BFA for 24 h, the level of ASPD staining was markedly reduced to 36% ± 13% (n = 3) of that without BFA treatment (see high-power images in the right, quantification results below in [Figure 9](#fig9){ref-type="fig"}). We also found that BFA treatment of MG132-treated APPswe-transduced neurons substantially decreased the ASPD and TGN38 signals in a time-dependent manner ([Figure S8](#mmc1){ref-type="supplementary-material"}). These results further support the idea that ASPD are mainly present in the TGN under steady-state conditions.Figure 9BFA Markedly Reduced ASPD AccumulationPrimary rat hippocampal neuronal cultures, with or without AAV-APPswe transduction, were treated with 75 nM MG132 for 24 h in the absence or presence of 0.6 μg/mL BFA. We determined this concentration by examining BFA concentrations from 0.6 to 10 μg/mL in our system and found that 0.6 μg/mL BFA treatment was enough to destroy the Golgi structure without affecting the cell viability. The cultures were triple-stained with rpASD1, anti-TGN38 antibody (TGN marker), and DAPI. Representative images are shown. High-power images on the right were obtained with a highly sensitive, direct photon-counting system with a 100X oil objective lens. Solid and hatched scale bars, 10 and 1 μm, respectively. See also representative images of control cultures without AAV transduction in [Figure S7](#mmc1){ref-type="supplementary-material"}. The total amount of rpASD1-immunostained ASPD detected in MAP2-positive neurons was determined by using an IN Cell Analyzer as in [Figure 4](#fig4){ref-type="fig"}B, right, and is shown as "ASPD level" below (mean ± SD, n = 3; Scheffé post hoc test, \*\*\*p \< 0.0001, \*\*p = 0.001).See [Figures S7](#mmc1){ref-type="supplementary-material"} and [S8](#mmc1){ref-type="supplementary-material"}.

We then examined the steady-state distribution of human APP770 and N-terAβ in APPswe-transduced mature neurons treated with MG132 for 24 h. As shown in [Figure S9](#mmc1){ref-type="supplementary-material"}, human APP770-specific signals increased most intensely in the TGN and also in the ER in APPswe-transduced neurons with MG132 treatment. In the case of N-terAβ staining, the signal was increased mainly in the *cis*-Golgi, and also on the TGN, the REs, and the ER surface, but was rarely observed in the early endosomes (EEs) or the Lys in our system ([Figures S10](#mmc1){ref-type="supplementary-material"} and [S11](#mmc1){ref-type="supplementary-material"}). In contrast, without MG132 treatment, the signal intensity of either human APP770 or N-terAβ was too weak to determine its subcellular distribution (representative images in [Figures S9--S11](#mmc1){ref-type="supplementary-material"}).

Finally, we performed a quantitative co-localization analysis of N-terAβ staining and ASPD staining with organelle markers in MG132-treated APPswe-transduced cells. As shown in [Figure 10](#fig10){ref-type="fig"}, although N-terAβ and ASPD co-localized to some extent with EEA1 and LAMP1-stained areas, the levels of co-localization in PDI-, GM130-, TGN38-, and TfR-stained areas were always substantially and significantly (p \< 0.0001 by Scheffé post hoc test, see legend in [Figure 10](#fig10){ref-type="fig"}) higher than those in EEA1- and LAMP1-stained areas. Interestingly, among PDI-, GM130-, TGN38-, and TfR-stained areas, the co-localization coefficients for N-terAβ were consistently significantly higher in GM130-stained areas, whereas the coefficients for ASPD were always significantly higher in TGN38-stained areas (p \< 0.0001 by Scheffé post hoc test, see the legend in [Figure 10](#fig10){ref-type="fig"}) in steady state.Figure 10Quantitative Co-localization AnalysesThe weighted colocalization coefficients were obtained using ZEN 2009 software (Zeiss) exactly according to the manufacturer\'s instructions (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The weighted colocalization coefficients represent the number of red pixels (rpASD1 or N-terAβ) that co-localize with green pixels (organelle markers) divided by the total number of red pixels. Analyses were performed using different sets of MG132-treated APP-expressing neurons. A representative scattergram is shown below. Statistical significance was calculated using Scheffé post hoc test (green asterisks: \*\*\*p \< 0.0001, \*\*p = 0.0008 \[for ASPD\] and 0.0019 \[for N-ter Aβ\], \*p = 0.021 \[for ASPD\] and 0.0316 \[for N-ter Aβ\], compared with negative control using DAPI staining; pink asterisks and black asterisks \*\*\*p \< 0.0001). See [Figures S9--S11](#mmc1){ref-type="supplementary-material"}.

ASPD Accumulate in the *Trans*-Golgi Network and the Recycling Endosomes of Mature Neurons Expressing APP Bearing the Osaka Mutation {#sec2.5}
------------------------------------------------------------------------------------------------------------------------------------

The Osaka mutation causes the deletion of a single amino acid, residue E693 (corresponding to E22 of Aβ). Because Aβ fibrils appeared to be absent in the brains of patients and mice carrying this mutation ([@bib69], [@bib68]), the mutation was believed to accelerate only the formation of Aβ oligomers. However, precise conformational and assembly kinetic studies of the mutant peptides *in vitro* revealed that the primary biophysical effect of this mutant is to accelerate conformational changes in the monomer that facilitate oligomerization and fibril formation ([@bib23]). To address whether this mutation facilitates ASPD formation in mature neurons, we first examined whether E22Δ-Aβ~1-42~ (Aβ~1-42~-osk) formed neurotoxic ASPD by using a toxicity assay, transmission electron microscopic analysis, and dot blotting with anti-ASPD antibody rpASD1 ([Figure 11](#fig11){ref-type="fig"}A). Interestingly, ASPD derived from Aβ~1-42~-osk were more toxic to mature hippocampal neurons than ASPD from wild-type Aβ~1-42~ (compare viability data at 18 nM in [Figure 11](#fig11){ref-type="fig"}A). Treatment of the APPosk-transduced neurons with 75 nM MG132 for 24 h led to a marked increase in both the number of the ASPD-containing neurons and the ASPD levels in each neuron (see [Figure 11](#fig11){ref-type="fig"}B), as observed in the case of the APPswe transduction, except that the ASPD level in each neuron was significantly lower in the case of APPosk transduction, compared with APPswe transduction (n = 3, p \< 0.0001 by Scheffé post hoc test, [Figure 11](#fig11){ref-type="fig"}B below). As observed in APPswe-transduced neurons, proteasome inhibition increased N-terAβ and human APP770 staining in almost all APPosk-expressing neurons ([Figures 2](#fig2){ref-type="fig"}), whereas ASPD accumulation was detected only in some of the N-terAβ-labeled neurons ([Figure S1](#mmc1){ref-type="supplementary-material"}). High-power images of these ASPD-containing APPosk-expressing neurons showed that ASPD staining was co-localized mainly with TGN38 and also with the cis-Golgi GM130 and the RE marker, TfR, as observed in the APPswe-expressing neurons, at 24-h MG132 treatment ([Figure 11](#fig11){ref-type="fig"}C). Finally, the Golgi-destroying BFA treatment confirmed that ASPD accumulated in the Golgi apparatus of the APPosk-transduced neurons ([Figure S12](#mmc1){ref-type="supplementary-material"}). Thus based on the findings in neurons expressing the two different APP transgenes, we conclude that the TGN is the primary site of ASPD accumulation in steady state in APP-expressing mature neurons.Figure 11ASPD Form from Aβ~1-42~-osk(A) Primary rat hippocampal neuronal cultures at 21 DIV were treated with synthetic ASPD produced either from Aβ~1-42~ or Aβ~1-42~-osk (E22Δ) at the indicated concentration for 24 h. Viability of each culture was determined by using highly water-soluble tetrazolium salt, WST-8, ([Transparent Methods](#mmc1){ref-type="supplementary-material"}; mean ± SD, n = 3; Scheffé post hoc test, \*\*\*p \< 0.0001 and \*\*p = 0.0007 compared with ASPD-untreated neurons; \*p = 0.0048 compared with Aβ~1-42~-osk-derived ASPD). Representative dot blotting (using anti-Aβ N-terminal 82E1 and ASPD-specific rpASD1 antibodies) and a representative transmission electron microscopic image of the negatively stained Aβ~1-42~-osk-derived ASPD (arrows) are shown on the right.(B) Primary rat hippocampal neuronal cultures with AAV-APPosk transduction were treated with 75 nM MG132 for the indicated time, stained, and photographed as in [Figure 4](#fig4){ref-type="fig"}B (left column). Representative images are shown. Scale bar, 50 μm. The ASPD staining of each culture was quantified using the In Cell Analyzer (GE Healthcare Lifesciences) as in [Figure 4](#fig4){ref-type="fig"}B (mean ± SD, n = 3; Scheffé post hoc test; \*\*\*p \< 0.0001, \*\*p \< 0.0005, \*p = 0.01).(C) Primary rat hippocampal neuronal cultures with AAV-APPosk transduction were treated with 75 nM MG132 for the indicated time, stained, and photographed as in [Figures 6](#fig6){ref-type="fig"} and [8](#fig8){ref-type="fig"}. High-power images were obtained with a highly sensitive, direct photon-counting system with a 100X oil objective lens. For the 24-h MG132 treatment, the single red or green image is also shown. Representative images are shown. Scale bar, 10 μm.See [Figures 2](#fig2){ref-type="fig"}, [S1](#mmc1){ref-type="supplementary-material"}, and [S12](#mmc1){ref-type="supplementary-material"}.

Intra-neuronal ASPD Are Secreted and Are Toxic to NAKα3-Expressing Neurons {#sec2.6}
--------------------------------------------------------------------------

Our previous studies have shown that NAKα3 is the only ASPD-binding protein that is directly linked to ASPD neurotoxicity ([@bib45]). ASPD bind to the extracellular region of NAKα3 located in the L7/8 extracellular loop encompassing Asn^879^ and Trp^880^ and induce neurodegeneration by inhibiting NAKα3 pump activity ([@bib45]). Accordingly, ASPD that form inside neurons should be secreted to be neurotoxic. We therefore examined whether intra-neuronal ASPD were secreted and exerted neurotoxicity against NAKα3-expressing neurons. To this end, we developed a chemiluminescent enzyme immunoassay (CLEIA) that selectively detects ASPD with two ASPD-specific antibodies (see scheme in [Figure 12](#fig12){ref-type="fig"}A). This ASPD-specific CLEIA system enabled us to detect ASPD in the picomolar range. It did not detect low-molecular-weight Aβ, mostly monomers and dimers, which passed through a 50-kDa molecular weight cutoff filter ([@bib80]) ([Figure 12](#fig12){ref-type="fig"}A). Note that in [Figures 12](#fig12){ref-type="fig"}A, 12B, and [S13](#mmc1){ref-type="supplementary-material"}, to enable easier comparison between ASPD and Aβ, the concentration of ASPD (128 kDa average mass; [@bib39]) is expressed in terms of Aβ~1-42~ monomer (4.53 kDa mass). We found that ASPD were recovered in the 10× concentrated 100-kDa retentate fraction of the culture supernate of the MG132-treated APPswe-transduced neurons at a concentration of 12.8 ± 4.8 pM (n = 3) ([Figure 12](#fig12){ref-type="fig"}B). ASPD were not detected in the 100-kDa flow-through fraction ([Figure S13](#mmc1){ref-type="supplementary-material"} left). The culture supernates of the MG132-treated APPswe-expressing neurons also contained Aβ~1-40~ and Aβ~1-42~ at 237.5 ± 53.7 pM and 39.9 ± 9.4 pM (n = 3), respectively, which were mostly recovered in the 100-kDa flow-through fraction ([Figure S13](#mmc1){ref-type="supplementary-material"} right). The ASPD level was below the detection limit in the 10× concentrated 100-kDa retentate fraction of the culture supernate of untransduced neurons ([Figure 12](#fig12){ref-type="fig"}B), which is in line with the quantification showing only a trace amount of ASPD formed in untransduced neurons ([Figure 4](#fig4){ref-type="fig"}B right). Before MG132 treatment, the ASPD levels were approximately 5.7 pM in the 10× concentrated 100-kDa retentates, suggesting that ASPD secretion increased after MG132 treatment.Figure 12Intra-neuronal ASPD Were Secreted and Kill NAKα3 Neurons(A) The CLEIA system was developed based on our previous enzyme-linked immunosorbent assay (ELISA) that selectively detected ASPD with two ASPD-specific antibodies ([@bib44]). The newly established ASPD-specific CLEIA (see a schematic image in upper panel and details in [Transparent Methods](#mmc1){ref-type="supplementary-material"}) detects picomolar levels of ASPD (expressed as Aβ monomer concentration) but does not respond to low-molecular-weight (LMW)-Aβ in the 50-kDa flow-through fraction. *R*^2^ = 0.99891 for ASPD and 0.01162 for LMW-Aβ.(B) ASPD level in culture supernates detected by ASPD-specific CLEIA in (A). A 10× concentrated culture supernate was obtained using 100-kDa filters from the neuronal cultures (with or without AAV-APPswe) treated with 75 nM MG132 for 24 h (see [Methods](#sec4){ref-type="sec"}). Aβ~1-40~ and Aβ~1-42~ were also quantified (see [Figure S13](#mmc1){ref-type="supplementary-material"}). Mean ± SD, n = 3.(C) APPswe-transduced or untransduced control neuronal cultures were treated with 75 nM MG132 for 24 h in the presence or absence of mASD3 antibody (1 ng/mL) that can block ASPD neurotoxicity ([@bib44]) and stained with anti-NAKα3 antibody and DAPI ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). The NAKα3 level was quantified using a Yokogawa CQ1 (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}; mean ± SD, n = 28 for MG132-treated control, 19 for mASD3-treated MG132-treated control, 52 for MG132-treated APPswe, or 31 for mASD3-treated MG132-treated APPswe; Scheffé post hoc test; \*\*\*p \< 0.0001). Representative images, used for the quantification, are shown with 100-μm scale bars. Note that NAKα3 was detected by an antibody that specifically recognizes an internal region of NAKα3 (SANTA CRUZ sc-16051-R). Therefore, ASPD binding to the extracellular region of NAKα3 does not interfere with the binding of the anti-NAKα3 antibody to NAKα3 ([@bib45]).(D) Culture supernates were collected from 24-h MG132-treated APPswe-transduced or untransduced control neuronal cultures. From the collected culture supernates, ASPD were immunodepleted by mASD3-covered magnetic beads, and another 22 DIV primary rat hippocampal neuronal culture was treated with the resulting immunodepleted culture supernates. As a control, the collected culture supernates were also incubated with normal mouse IgG-covered magnetic beads (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The NAKα3 level was quantified as in (C) after 24 h. Mean ± SD, n = 8, Scheffé post hoc test; \*p = 0.0172 compared with IgG-treated control supernate. Representative images, used for the quantification, are shown with 100-μm scale bars.See [Figure S13](#mmc1){ref-type="supplementary-material"}

We next examined whether NAKα3-expressing neurons degenerated in the MG132-treated AAV-APPswe-transduced cells. The level of NAKα3-expressing neurons in MG132-treated AAV-APPswe-transduced cultures significantly decreased to 72.9% ± 23.9% (n = 52) of that in MG132-treated untransduced cultures (\*\*\*p \< 0.0001 by Scheffé post hoc test), which correlated with the ASPD amounts in culture supernates. Previously, we showed that pretreatment of mASD3 antibody (with a *K*~*d*~ of 0.003 nM for ASPD) specifically blocked ASPD neurotoxicity against mature neurons ([@bib44]). Consistent with this observation, the addition of an excess amount of mASD3 antibody in culture media of MG132-treated AAV-APPswe-transduced mature neurons completely blocked the decrease in NAKα3-expressing neurons ([Figure 12](#fig12){ref-type="fig"}C). We confirmed that incubation of MG132-treated untransduced mature neurons with mASD3 antibody did not affect the level of NAKα3-expressing neurons ([Figure 12](#fig12){ref-type="fig"}C). Given that antibodies usually do not cross the cell membrane, these results demonstrate that secreted ASPD caused the neurodegeneration observed in the MG132-treated AAV-APPswe-transduced mature neurons.

To further test our claim, we collected culture media from MG132-treated APPswe-transduced or untransduced cultures and applied them to untransduced mature neurons. Before application, ASPD were immunodepleted from the collected media by 1-h incubation with mASD3-antibody-covered magnetic beads. As a control, the collected media were separately incubated with normal mouse-IgG-covered magnetic beads. As clearly shown in [Figure 12](#fig12){ref-type="fig"}D, the collected media that were incubated with normal IgG induced degeneration in NAKα3-expressing neurons. This neurodegeneration was not observed when ASPD in the media were immunodepleted by prior incubation with mASD3-antibody-covered magnetic beads ([Figure 12](#fig12){ref-type="fig"}D). These results collectively demonstrate that ASPD were secreted and were toxic to NAKα3-expressing neurons.

We next performed detailed viability analyses of the ASPD-producing neurons. WST-8 assay ([Figure 13](#fig13){ref-type="fig"}A) showed that the viability of the APPswe-transduced mature hippocampal neurons at 21 DIV was lower than that of the untransduced neurons before the MG132 treatment (p = 0.089 by Scheffé post hoc test; n = 3). The 24-h MG132 treatment further reduced the viability of the APPswe-transduced mature hippocampal neurons ([Figure 13](#fig13){ref-type="fig"}A). Similar results were obtained with APPosk-transduced neurons ([Figure 13](#fig13){ref-type="fig"}A). The viability of the APPosk-transduced mature hippocampal neurons was significantly lower than that of the untransduced neurons before the MG132 treatment (\*\*p = 0.0268 by Scheffé post hoc test; n = 3), and the 24-h MG132 treatment further reduced the viability of the APPosk-transduced neurons ([Figure 13](#fig13){ref-type="fig"}A). We confirmed that neither 24-h MG132 treatment nor AAV transduction of GFP itself affected cell viability ([Figure 13](#fig13){ref-type="fig"}A). Taken together, the viability of the neurons declined concomitantly with the accumulation of ASPD.Figure 13Secreted ASPD Induced Apoptotic Degeneration of Surrounding Neurons(A) APP- or GFP-transduced or untransduced control neuronal cultures were treated with 75 nM MG132 for the indicated time. Viability was determined with a Cell Counting Kit-8 (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}; mean ± SD, n = 3; Scheffé post hoc test, \*\*\*p \< 0.0001, \*\*p = 0.0268). The viability of GFP-transduced cultures was 93.5% ± 7.0% of that of the untransduced control cultures (n = 3, p = 0.1854 by Scheffé posy hoc test), indicating that AAV transduction itself does not affect cell viability.(B) APP-transduced or untransduced control cultures were treated with 75 nM MG132 for the indicated time and stained with the anti-ASPD rpASD1 antibody, DAPI, and TUNEL (arrowhead) or with the anti-MAP2 antibody ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). Solid and hatched scale bars, 50 and 100 μm, respectively.(C) APP-transduced or untransduced control cultures were treated with or without 75 nM MG132 for 24 h and quadruple-stained with rpASD1, DAPI, TUNEL, and MAP2/GFAP. The number of MAP2-labeled neurons or GFAP-labeled astrocytes in APPswe-transduced cultures was counted and is shown (n = 7, Scheffé post hoc test, \*\*\*p \< 0.0001). Representative images are shown in [Figure S14](#mmc1){ref-type="supplementary-material"}.(D) APPswe-transduced primary rat hippocampal neuronal cultures were treated with 75 nM MG132 for the indicated time; triple-stained with propidium iodide (PI), calcein-AM, and anti-ASPD mASD3 antibody (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}); and photographed (see [Figure S15](#mmc1){ref-type="supplementary-material"}). Representative images of the corresponding PI/mASD3 staining are shown with 50-μm scale bars. PI-detectable non-apoptotic death was detected in ASPD-producing neurons at 48-h MG132 treatment.See [Figures S14](#mmc1){ref-type="supplementary-material"} and [S15](#mmc1){ref-type="supplementary-material"}.

We next examined whether apoptotic cell death occurred in these neurons by detecting DNA fragmentation using TUNEL staining. To our surprise, TUNEL-positive apoptosis did not occur in the ASPD-producing neurons but did occur in the neurons surrounding these ASPD-positive neurons (arrowhead in [Figure 13](#fig13){ref-type="fig"}B, left and middle columns, and S14). MAP2 immunostaining showed a marked reduction of neurons in the APPswe- and APPosk-transduced mature neuronal cultures treated with 75 nM MG132 for 24 h ([Figures 13](#fig13){ref-type="fig"}B right and S14). We counted the number of MAP2- or GFAP-positive cells in MG132-treated AAV-APPswe-transduced cultures that were double stained with TUNEL and MAP2/GFAP and found that, after 24-h MG132 treatment, on an average 54% of MAP2-positive neurons was lost in APPswe-transduced cells (n = 7), whereas the number of GFAP-positive astrocytes was not changed ([Figures 13](#fig13){ref-type="fig"}C and [S14](#mmc1){ref-type="supplementary-material"}). Following apoptotic cell death in the surrounding neurons, the ASPD-producing neurons themselves degenerated after 48 h of 75 nM MG132 treatment, as indicated by propidium iodide (PI) staining ([Figure 13](#fig13){ref-type="fig"}D, see also arrowheads in [Figure S15](#mmc1){ref-type="supplementary-material"}). PI-detectable, non-apoptotic neurodegeneration was rarely observed until 24-h MG132 treatment ([Figures 13](#fig13){ref-type="fig"}D and [S15](#mmc1){ref-type="supplementary-material"}). This suggests that the ASPD-producing neurons either die very slowly or degenerate due to the lack of synaptic inputs from the surrounding neurons.

ASPD Appear to Primarily Form in Excitatory Neurons {#sec2.7}
---------------------------------------------------

In [Figures 4](#fig4){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}, we showed that ASPD increased in only a limited population of neurons. Therefore we examined in which type of neurons the intra-neuronal ASPD increase. We first showed that the AAV transduction ratio did not vary according to the neuronal subtype by introducing non-toxic GFP (as shown in [Figure 13](#fig13){ref-type="fig"}A) by AAV. As shown in [Figure S16](#mmc1){ref-type="supplementary-material"}, GFP was transduced to almost all neurons, irrespective of Math2-positive excitatory neurons ([@bib61]) (99.1% ± 1.4%, n = 30) or parvalbumin (PV)-positive GABAergic interneurons (97.0% ± 3.7%, n = 30; see representative images of [Figure S16](#mmc1){ref-type="supplementary-material"}). Although APPswe transduction itself does not seem to affect the ratio between Math2-positive excitatory neurons and PV-labeled interneurons ([Figure S17](#mmc1){ref-type="supplementary-material"}), interestingly, most of the Math2-positive excitatory neurons accumulated ASPD (84% ± 14%, n = 6), whereas most of the PV-labeled interneurons did not accumulate ASPD (8.7% ± 10.0%, n = 24) ([Figure 14](#fig14){ref-type="fig"}). We also examined calbindin-labeled neurons, which are mostly inhibitory neurons ([@bib40]) and found that most of the calbindin-positive inhibitory neurons did not accumulate ASPD (9.0% ± 3.2%, n = 5) ([Figure S18](#mmc1){ref-type="supplementary-material"}). Thus it appears that ASPD primarily form in the excitatory neurons and are secreted from these neurons, exhibiting neurotoxicity toward the surrounding NAKα3-expressing neurons (Graphical Abstract; see [Discussion](#sec3){ref-type="sec"}).Figure 14ASPD Accumulate Only in Excitatory NeuronsAPPswe-transduced neuronal cultures were treated with 75 nM MG132 for 24 h and stained with the indicated antibodies. The ratio of the ASPD-containing neurons among either MAP2/PV or MAP2/Math2 double-positive neurons was quantified using a Yokogawa CQ1 (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}; inset, mean ± SD, n = 6 for MAP2/Math, 24 for MAP2/PV). ASPD were detected by anti-ASPD rpASD1 or mASD3 antibody. GABAergic interneurons are composed of a highly diverse population of inhibitory neurons, which represent about 20% of cortical/hippocampal neurons ([@bib1]). For quantification purposes, we used an antibody against PV, because PV-labeled interneurons represent ∼40% of the total number of GABAergic interneurons in the CA1 and CA3 of hippocampus ([@bib51]) and the PV antibody clearly stains the neuronal cell body. Representative images, used for the quantification, are shown with 100 μm scale bars. See control data in [Figures S16](#mmc1){ref-type="supplementary-material"} and [S17](#mmc1){ref-type="supplementary-material"} and calbindin data in [Figure S18](#mmc1){ref-type="supplementary-material"}. See [Figures S16--18](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In AD, Aβ oligomers accumulate in the brain. This accumulation might arise because of defects in APP processing or Aβ degradation, a shift in Aβ profiles to longer Aβs, or a change in Aβ assembly propensity caused by biological or chemical factors ([@bib18]). Here we studied how impairment of the proteasome function affected APP/Aβ turnover and oligomer formation. We found that the inhibition of proteasomes by a variety of inhibitors led to higher levels of ASPD in steady state by increasing Aβ levels in APP-expressing neurons and triggered changes in the subcellular distribution of ASPD from the axon to dendrites. Interestingly, ASPD appeared to form primarily in excitatory neurons and were secreted into the medium, leading to apoptotic death of surrounding NAKα3-expressing neurons ([Figure 12](#fig12){ref-type="fig"}). This is consistent with our previous finding that ASPD bind to NAKα3 on synapses and cause neuronal degeneration by inactivating NAKα3 pump activity ([@bib45]). NAKα3 neurons died apoptotically due to secreted ASPD, whereas ASPD-producing neurons that killed NAKα3 neurons died slowly and non-apoptotically ([Figures 13](#fig13){ref-type="fig"}, [S14](#mmc1){ref-type="supplementary-material"}, and [S15](#mmc1){ref-type="supplementary-material"}).

In using APP-overexpressing neurons as a model, we are aware that some phenotypes of APP-overexpressing mice models, such as sudden death, may be the result of APP overexpression per se and thus may not be reflective of the disease process in humans ([@bib57]). Nevertheless, these mouse APP overexpression model systems have proved to be useful and relevant in numerous studies of the production or deposition of Aβ ([@bib57]). In our system, as shown in [Figure 11](#fig11){ref-type="fig"}B, MG132 treatment substantially and significantly (p \< 0.0001 by Scheffé post hoc test) increased the levels of ASPD and the number of ASPD-containing neurons, relative to control neurons, suggesting that the effects we observed were not merely due to APP overexpression. More importantly, intra-neuronal accumulation of ASPD is indeed present in the brains of patients with AD ([@bib44]). The AAV-APP system used in this work thus appears capable of revealing how ASPD may form in neurons in the human brain and affect disease pathology.

We showed that proteasome inhibition led to an increase in Aβ in steady state, by inhibiting ERAD-mediated degradation of Aβ or APP, without affecting its secretion ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [S2](#mmc1){ref-type="supplementary-material"}). The rate-limiting step in ERAD is ubiquitination performed by ER-membrane-anchored E3 ubiquitin ligases, which seem to target only a small number of proteins. Recent studies have identified several E3 ubiquitin ligases for APP that directly interact with APP and mediate APP degradation by proteasomes ([@bib25], [@bib34], [@bib75], [@bib77]). Notably, gene suppression of one of the E3 ubiquitin ligases for APP, hydroxymethylglutaryl-coenzyme A reductase degradation protein 1 (HRD1), leads to APP accumulation and an increase in Aβ production, and vice versa ([@bib25]). MG132 inhibits APP degradation induced by increased HRD1 expression ([@bib25]). In the case of Aβ, another E3 ubiquitin ligase, parkin, promotes proteasome-mediated clearance of Aβ~1-42~ in neurons ([@bib5]). This is consistent with findings in a parkin-null mouse model, where the accumulation of Aβ deposits was observed in the brain even without modification of APP, presenilins, or secretases ([@bib53]). These findings support the notion that proteasomes may play a role in regulating APP/Aβ metabolism. Our findings demonstrate a link between ASPD levels and proteasome function, which may have important implications for AD pathophysiology. It will be interesting in the future to determine which E3 ubiquitin ligases or other regulators of APP/Aβ degradation are indeed involved in increasing ASPD formation.

Previous reports have shown that Aβ can be generated in all possible compartments of the secretory pathways, including the ER ([@bib13], [@bib17], [@bib20]), the TGN ([@bib17], [@bib81]), the PM ([@bib11], [@bib66]), the endosomes ([@bib16], [@bib32], [@bib48]), and the lysosomes ([@bib82]). We consistently detected the N-terminal end of Aβ (N-terAβ) in steady state in compartments ranging from the ER to the lysosomes ([Figure 10](#fig10){ref-type="fig"}). Among the possible compartments, the subcellular localization of BACE suggested that either the TGN or endosomes would serve as the locus of Aβ production. Recent studies have emphasized the role of EEs in Aβ production, because blocking endocytosis reduces Aβ production ([@bib7], [@bib48]), whereas enhancing endocytosis increases it ([@bib16]). Proteins related to endocytosis have been reported to be involved in APP processing ([@bib56], [@bib59], [@bib72]) (see also review [@bib50]). However, these studies do not rule out a role for the TGN in β-cleavage. For example, fluorescence resonance energy transfer analyses have shown that APP and BACE interact at least in the GM130-detected *cis*-Golgi, in addition to at the cell surface and in the EEs ([@bib29]). Aβ40 has been reported to be generated in the TGN depending on retromer-mediated APP recycling from the EEs to the TGN ([@bib10]). Accumulating data support the importance of the sorting mechanisms that transport APP and BACE from the cell surface to the endosomes and from the endosomes to the TGN. The exact location of APP processing will depend on the balance of traffic of APP and secretases. Therefore some discrepancies in existing data may derive from the use of different cell types and conditions. In particular, to establish and maintain functionally distinct domains in membranes, neurons have developed trafficking systems to deliver transmembrane proteins to the correct compartments ([@bib35]). Accordingly, the trafficking and processing of APP in highly polarized neurons might well be different from the processes in non-neuronal cells. For example, the sorting signal(s) mediating transport of APP to the axon or dendrites in neurons is completely different from that mediating the basolateral transport in MDCK cells ([@bib2], [@bib65]). In our system, ASPD signals were broadly distributed in steady state, but the TGN was shown to be the initial and highest localization site of ASPD in APP-expressing neurons ([Figures 6](#fig6){ref-type="fig"} and [10](#fig10){ref-type="fig"}). This suggests the possibility that ASPD may form mainly in the TGN. However, other possibilities cannot be excluded given the close and dynamic cross talk between TGN and endosomes ([@bib58]). Real-time imaging that enables detection of ASPD separately from Aβ monomers in mature neurons is needed to give a more definitive answer as to the exact location of ASPD formation in mature neurons. Interestingly, ASPD are present not only in the TGN, but also in the REs, which lie between the ER-TGN system and the endosome system. Because the RE serves as a hub to direct proteins to the PM, it is possible that the REs serve as a port for ASPD to be secreted. The REs, which are clustered tightly near the nucleus in close proximity to the TGN in non-neuronal cells, are spread almost evenly throughout the cell body, dendrites, and the axons in neurons ([@bib76]). One may speculate that axon-directed REs or dendrite-directed REs separately serve as hubs to direct ASPD to the axons or dendrites. We showed in [Figure 5](#fig5){ref-type="fig"}B that some population of dendritic ASPD co-localizes with Bassoon, suggesting that ASPD could be released at synapses. This observation is consistent with our previous study showing that ASPD bind to the pre-synaptic side of the neuron to induce neurodegeneration ([@bib44]). [Scheme 1](#sch1){ref-type="fig"} integrates our results with those extant.Scheme 1Steady-State Distribution of APP, N-terminal end of Aβ, and ASPD, Detected in This Work under Physiological Conditions without Proteasome Inhibition and with Proteasome Inhibition, Integrated with Previous Findings as to APP Degradation and TraffickingIn mature neurons, APP was widely detected in the ER-TGN as reported previously ([@bib17], [@bib20], [@bib81]). Proteasome inhibition leads to a higher steady-state level of APP and N-terAβ in APP-expressing neurons, possibly by inhibiting ERAD (see text). Under physiological conditions without proteasome inhibition, N-terAβ staining is too weak to allow its subcellular distribution to be determined (representative images in [Figures S10](#mmc1){ref-type="supplementary-material"} and [S11](#mmc1){ref-type="supplementary-material"}). From the red enhanced images, it appears that the weak N-terAβ signal is co-localized with the ER or the *cis*-Golgi, but not with the TGN, the EE, the RE, or the Lys ([Figures S10](#mmc1){ref-type="supplementary-material"} and [S11](#mmc1){ref-type="supplementary-material"}). After 24-h MG132 treatment, N-terAβ staining was detected mainly in the *cis*-Golgi, and also on the TGN, the RE, and the ER surface, but was rarely observed in the EE or the Lys in our system ([Figures 10](#fig10){ref-type="fig"}, [S10](#mmc1){ref-type="supplementary-material"}, and [S11](#mmc1){ref-type="supplementary-material"}). In the case of ASPD, a limited amount of ASPD was detected mainly in the TGN under physiological conditions ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}). With proteasome inhibition, the steady-state level of ASPD increased markedly, in particular, in the TGN, and also in the *cis*-Golgi and the RE. ASPD were also detected to some extent in the ER, and a very few were present in the EE and the Lys. Proteasome inhibition changes both N-terAβ and ASPD distribution from axons to dendrites ([Figures 5](#fig5){ref-type="fig"} and [S19](#mmc1){ref-type="supplementary-material"}). Blue arrows, APP; green arrows, N-terAβ; pink arrows, ASPD. Higher levels of APP and N-terAβ were detected after inhibiting ERAD (see text). Hatched brown arrows show possible cross-talk reported previously. N, nucleus; ER, endoplasmic reticulum; TGN, *trans*-Golgi network; PM, plasma membrane; EE, early endosome; RE, recycling endosome; LE/Lys, late endosome and lysosome.

Previously, we observed substantial accumulation of ASPD in the cerebral cortex and little accumulation in the cerebellum ([@bib45]). These findings strongly suggest that there exist regional or cell-type differences in ASPD accumulation. Consistently, we found that only excitatory neurons appear to form ASPD ([Figure 14](#fig14){ref-type="fig"}). This may be due to factors intrinsic to these cells that affect assembly propensity or it may be that only inhibitory neurons have a degradation system for ASPD, about which we do not know anything. Interestingly, proteasome inhibition led to a distribution change of both ASPD and Aβ from axons to dendrites ([Figures 5](#fig5){ref-type="fig"} and [S19](#mmc1){ref-type="supplementary-material"}), suggesting the presence of a common mechanism underlying this distribution change. The reason why such a change in ASPD delivery occurs remains to be established, as do the molecular mechanisms of ASPD secretion. Neurons have specialized Golgi compartments called "Golgi outposts" within dendritic arbors, which are essential for the proper elaboration of dendrites and neuronal polarity ([@bib35]). Golgi outposts are discontinuous from the somatic Golgi and are frequently localized at dendritic branch points ([@bib35]). Aβ and ASPD might use this system to be delivered to dendrites. We found that after 24 h of MG132 treatment the Golgi structure appeared to be fragmented in most of the APPswe-transduced neurons. Because the Golgi did not appear to be fragmented and ASPD had already accumulated at the TGN at 6-h MG132 treatment ([Figure 6](#fig6){ref-type="fig"}), it is unlikely that Golgi fragmentation causes ASPD accumulation at the TGN. Golgi fragmentation enhances vesicle budding and accelerates protein trafficking ([@bib76]), and reversible fragmentation has been detected in hyperactive neurons ([@bib67]). We therefore speculate that Golgi fragmentation at 24-h MG132 treatment might be a compensatory reaction to allow faster protein trafficking when the cells are under stress.

In this work, we found that Aβ~1-42~-osk (E22Δ-Aβ~1-42~) forms ASPD. As shown in quantification in [Figure 11](#fig11){ref-type="fig"}, the formation ratio of ASPD from Aβ~1-42~-osk was lower than that of ASPD from wild-type Aβ~1-42~ in APPswe-transduced neurons. Nevertheless, the total cell death level of the APPosk-transduced cultures was equivalent to that of the APPswe-transduced cultures, as shown by viability assay, MAP2 staining, and TUNEL staining ([Figures 13](#fig13){ref-type="fig"}A, 13B, and [S14](#mmc1){ref-type="supplementary-material"}). This could be due to increased toxicity of the ASPD derived from Aβ~1-42~-osk compared with that of ASPD derived from wild-type Aβ~1-42~. Our previous solution nuclear magnetic resonance (NMR) analysis of ASPD showed that the E22 residue resides in a core region of ASPD ([@bib45]). Therefore it is unlikely that E22 directly affects ASPD binding to NAKα3. It is more likely that the E22Δ mutation alters the conformation of the Aβ monomer ([@bib23]), which leads to differences in the structure of ASPD. Further solution NMR studies will be needed to determine at the atomic level precisely how the deletion of E22 changes the structure of ASPD and thus their toxicity.

Biomarker studies on humans indicate that accumulation of Aβ precedes the clinical onset of AD by more than a decade ([@bib78]). Notably, western blot analyses of human brains obtained from the Nun study showed distinct trends in levels of dimers, trimers, and dodecamers, according to the disease stage, suggesting that dodecamers might form earlier than trimers or dimers ([@bib36]). However, the lack of specific antibodies makes it difficult to monitor their actual formation. We have identified ASPD from brains of patients with AD as the key species responsible for neurodegeneration and also obtained ASPD-specific antibodies that could specifically detect the native tertiary structure of ASPD ([@bib44], [@bib45]). Building on that work, we established a mature neuron-derived system that was usable to monitor where ASPD form. As described above, the sorting and processing mechanisms of APP in neurons are expected to be more complicated than those in non-neuronal cells owing to dynamic cross talk between the TGN and the endosome system. Disturbances in these complex sorting and processing systems in neurons could affect Aβ production and have been linked to AD pathogenesis. Thus the mature neuron-based system established in the present work, and the findings resulting from its use, should further deepen our understanding of how Aβ assemblies may form in the human brain.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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